IMCR

Immunocore Holdings plc is a commercial-stage biotechnology company pioneering the development of T cell receptor (TCR) therapies for cancer treatment. The company's proprietary ImmTAC technology platform generates bi-specific biologics capable of redirecting T cells to recognize and destroy cancer cells. Immunocore's lead product, Kimmtrak, is approved for treating uveal melanoma. The company maintains a robust pipeline of TCR-based therapies targeting various solid tumors and hematological cancers. Immunocore's innovative approach represents a novel mechanism in cancer immunotherapy.